Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models.

Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ.

Mol Cancer Ther. 2019 Oct 9. pii: molcanther.0414.2019. doi: 10.1158/1535-7163.MCT-19-0414. [Epub ahead of print]

PMID:
31597714
2.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaax0720. doi: 10.1126/scitranslmed.aax0720.

PMID:
31578241
3.

Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement.

Lofano G, Gorman MJ, Yousif AS, Yu WH, Fox JM, Dugast AS, Ackerman ME, Suscovich TJ, Weiner J, Barouch D, Streeck H, Little S, Smith D, Richman D, Lauffenburger D, Walker BD, Diamond MS, Alter G.

Sci Immunol. 2018 Aug 17;3(26). pii: eaat7796. doi: 10.1126/sciimmunol.aat7796.

4.

Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies.

Mabuka JM, Dugast AS, Muema DM, Reddy T, Ramlakhan Y, Euler Z, Ismail N, Moodley A, Dong KL, Morris L, Walker BD, Alter G, Ndung'u T.

Front Immunol. 2017 Sep 8;8:1104. doi: 10.3389/fimmu.2017.01104. eCollection 2017.

5.

Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV.

Dugast AS, Arnold K, Lofano G, Moore S, Hoffner M, Simek M, Poignard P, Seaman M, Suscovich TJ, Pereyra F, Walker BD, Lauffenburger D, Kwon DS, Keele BF, Alter G.

Clin Infect Dis. 2017 Apr 15;64(8):1098-1104. doi: 10.1093/cid/cix057.

6.

Assessment of the antiviral capacity of primary natural killer cells by optimized in vitro quantification of HIV-1 replication.

He X, Simoneau CR, Granoff ME, Lunemann S, Dugast AS, Shao Y, Altfeld M, Körner C.

J Immunol Methods. 2016 Jul;434:53-60. doi: 10.1016/j.jim.2016.04.007. Epub 2016 Apr 16.

7.

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, Boesch AW, Streeck H, Kwon DS, Ackerman ME, Suscovich TJ, Brouckaert P, Schacker TW, Alter G.

Mucosal Immunol. 2016 Nov;9(6):1584-1595. doi: 10.1038/mi.2016.12. Epub 2016 Feb 17.

8.

Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics.

Li JZ, Arnold KB, Lo J, Dugast AS, Plants J, Ribaudo HJ, Cesa K, Heisey A, Kuritzkes DR, Lauffenburger DA, Alter G, Landay A, Grinspoon S, Pereyra F.

Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117. doi: 10.1093/ofid/ofu117. eCollection 2015 Jan.

9.

HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN.

Cohen KW, Dugast AS, Alter G, McElrath MJ, Stamatatos L.

J Immunol. 2015 Mar 15;194(6):2769-75. doi: 10.4049/jimmunol.1400952. Epub 2015 Feb 9.

10.

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G.

Eur J Immunol. 2014 Oct;44(10):2925-37. doi: 10.1002/eji.201344305. Epub 2014 Aug 11.

11.

KIR2DS4 promotes HIV-1 pathogenesis: new evidence from analyses of immunogenetic data and natural killer cell function.

Merino AM, Dugast AS, Wilson CM, Goepfert PA, Alter G, Kaslow RA, Tang J.

PLoS One. 2014 Jun 5;9(6):e99353. doi: 10.1371/journal.pone.0099353. eCollection 2014.

12.

Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies.

Dugast AS, Chan Y, Hoffner M, Licht A, Nkolola J, Li H, Streeck H, Suscovich TJ, Ghebremichael M, Ackerman ME, Barouch DH, Alter G.

PLoS One. 2014 May 12;9(5):e97229. doi: 10.1371/journal.pone.0097229. eCollection 2014.

13.

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, Mahan AE, Liao L, Streeck H, Andrews C, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Kaewkungwal J, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellogg C, Ackerman ME, Alter G.

Sci Transl Med. 2014 Mar 19;6(228):228ra38. doi: 10.1126/scitranslmed.3007736.

14.

Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Lai JI, Licht AF, Dugast AS, Suscovich T, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME.

J Virol. 2014 Mar;88(5):2799-809. doi: 10.1128/JVI.03130-13. Epub 2013 Dec 18.

15.

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL.

Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24.

16.

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity.

Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast AS, Heizen EL, Ercan A, Choi I, Streeck H, Nigrovic PA, Bailey-Kellogg C, Scanlan C, Alter G.

J Clin Invest. 2013 May;123(5):2183-92. doi: 10.1172/JCI65708. Epub 2013 Apr 8.

17.

Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Ackerman ME, Dugast AS, McAndrew EG, Tsoukas S, Licht AF, Irvine DJ, Alter G.

J Virol. 2013 May;87(10):5468-76. doi: 10.1128/JVI.03403-12. Epub 2013 Mar 6.

18.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR.

J Infect Dis. 2013 Jan 15;207(2):248-56. doi: 10.1093/infdis/jis671. Epub 2012 Nov 2.

19.

High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples.

Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME.

J Immunol Methods. 2012 Dec 14;386(1-2):117-23. doi: 10.1016/j.jim.2012.09.007. Epub 2012 Sep 27.

20.

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES, Dugast AS, Hermanus T, Goulder PJ, Coovadia HM, Werner L, Morris L, Alter G, Derdeyn CA, Ndung'u T.

Virology. 2012 Nov 25;433(2):410-20. doi: 10.1016/j.virol.2012.08.033. Epub 2012 Sep 18.

21.

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR.

J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.

22.

Determining the phagocytic activity of clinical antibody samples.

McAndrew EG, Dugast AS, Licht AF, Eusebio JR, Alter G, Ackerman ME.

J Vis Exp. 2011 Nov 30;(57):e3588. doi: 10.3791/3588.

23.

Emerging concepts on the role of innate immunity in the prevention and control of HIV infection.

Ackerman ME, Dugast AS, Alter G.

Annu Rev Med. 2012;63:113-30. doi: 10.1146/annurev-med-050310-085221. Epub 2011 Nov 8. Review.

PMID:
22077718
24.

Altered distribution of mucosal NK cells during HIV infection.

Sips M, Sciaranghella G, Diefenbach T, Dugast AS, Berger CT, Liu Q, Kwon D, Ghebremichael M, Estes JD, Carrington M, Martin JN, Deeks SG, Hunt PW, Alter G.

Mucosal Immunol. 2012 Jan;5(1):30-40. doi: 10.1038/mi.2011.40. Epub 2011 Oct 12.

25.

Early viral replication in lymph nodes provides HIV with a means by which to escape NK-cell-mediated control.

Luteijn R, Sciaranghella G, van Lunzen J, Nolting A, Dugast AS, Ghebremichael MS, Altfeld M, Alter G.

Eur J Immunol. 2011 Sep;41(9):2729-40. doi: 10.1002/eji.201040886. Epub 2011 Aug 12.

26.

Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.

Dugast AS, Tonelli A, Berger CT, Ackerman ME, Sciaranghella G, Liu Q, Sips M, Toth I, Piechocka-Trocha A, Ghebremichael M, Alter G.

Virology. 2011 Jul 5;415(2):160-7. doi: 10.1016/j.virol.2011.03.012. Epub 2011 May 12.

27.

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.

Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G.

J Immunol Methods. 2011 Mar 7;366(1-2):8-19. doi: 10.1016/j.jim.2010.12.016. Epub 2010 Dec 27. Erratum in: J Immunol Methods. 2012 Feb 28;376(1-2):156.

28.

MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction.

Nolting A, Dugast AS, Rihn S, Luteijn R, Carrington MF, Kane K, Jost S, Toth I, Nagami E, Faetkenheuer G, Hartmann P, Altfeld M, Alter G.

Virology. 2010 Oct 10;406(1):12-20. doi: 10.1016/j.virol.2010.05.014. Epub 2010 Jul 29.

29.

Trophic and immunoregulatory properties of neural precursor cells: benefit for intracerebral transplantation.

Michel-Monigadon D, Bonnamain V, Nerrière-Daguin V, Dugast AS, Lévèque X, Plat M, Venturi E, Brachet P, Anegon I, Vanhove B, Neveu I, Naveilhan P.

Exp Neurol. 2011 Jul;230(1):35-47. doi: 10.1016/j.expneurol.2010.04.021. Epub 2010 May 11.

PMID:
20470774
30.

Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation.

Rossignol J, Boyer C, Thinard R, Remy S, Dugast AS, Dubayle D, Dey ND, Boeffard F, Delecrin J, Heymann D, Vanhove B, Anegon I, Naveilhan P, Dunbar GL, Lescaudron L.

J Cell Mol Med. 2009 Aug;13(8B):2547-58. doi: 10.1111/j.1582-4934.2009.00657.x.

31.

Autoimmune responses against renal tissue proteins in long-term surviving allograft recipients.

Fang C, Ballet C, Dugast AS, Godard A, Moreau A, Usal C, Smit H, Vanhove B, Brouard S, Harb J, Soulillou JP.

Transpl Int. 2009 Nov;22(11):1091-9. doi: 10.1111/j.1432-2277.2009.00923.x. Epub 2009 Jul 16.

32.

Immune regulation by non-lymphoid cells in transplantation.

Dugast AS, Vanhove B.

Clin Exp Immunol. 2009 Apr;156(1):25-34. doi: 10.1111/j.1365-2249.2009.03877.x. Epub 2009 Jan 22. Review.

33.

Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion.

Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, Vuillefroy de Silly R, Usal C, Smit H, Martinet B, Thebault P, Renaudin K, Vanhove B.

J Immunol. 2008 Jun 15;180(12):7898-906.

34.

Implication of matrix metalloproteinase 7 and the noncanonical wingless-type signaling pathway in a model of kidney allograft tolerance induced by the administration of anti-donor class II antibodies.

Jovanovic V, Dugast AS, Heslan JM, Ashton-Chess J, Giral M, Degauque N, Moreau A, Pallier A, Chiffoleau E, Lair D, Usal C, Smit H, Vanhove B, Soulillou JP, Brouard S.

J Immunol. 2008 Feb 1;180(3):1317-25.

35.

Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance.

Haudebourg T, Dugast AS, Coulon F, Usal C, Triebel F, Vanhove B.

Transplantation. 2007 Dec 15;84(11):1500-6.

PMID:
18091527
36.

Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients.

Guillonneau C, Séveno C, Dugast AS, Li XL, Renaudin K, Haspot F, Usal C, Veziers J, Anegon I, Vanhove B.

J Immunol. 2007 Dec 15;179(12):8164-71.

37.

Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells.

Haspot F, Séveno C, Dugast AS, Coulon F, Renaudin K, Usal C, Hill M, Anegon I, Heslan M, Josien R, Brouard S, Soulillou JP, Vanhove B.

Am J Transplant. 2005 Oct;5(10):2339-48.

Supplemental Content

Loading ...
Support Center